Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.

Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.
复制标题

醋酸戈舍瑞林联合或不联合抗雄激素或雌激素治疗晚期前列腺癌患者：日本的一项多中心、随机、对照试验。

DOI：
--
复制
发表时间：
1999
期刊：
Japanese Journal of Clinical Oncology
影响因子：
2.4
通讯作者：
Yasuo Ohashi
Yasuo Ohashi
中科院分区：
医学4区
文献类型：
--
作者：
Toshihiko Kotake;Michiyuki Usami;Hideyuki Akaza;K. Koiso;Y. Homma;Kazuki Kawabe;Yoshio Aso;S. Orikasa;Jun Shimazaki;Shigeo Isaka;Osamu Yoshida;Y. Hirao;Eijiro Okajima;Seiji Naito;J. Kumazawa;Hiroshi Kanetake;Y. Saito;Yoshitada Ohi;Yasuo Ohashi

文献摘要

被引文献

相似文献

目的 本随机对照研究的目的是研究促黄体生成素释放激素激动剂醋酸戈舍瑞林长期单药治疗与短期和长期联合雄激素阻断的疗效和安全性。 方法 晚期前列腺癌患者（n = 371）随机接受醋酸戈舍瑞林单独治疗或醋酸戈舍瑞林加长期或短期抗雄激素（醋酸氯地孕酮）或短期雌激素（二磷酸己烯雌酚）的联合治疗。 结果 治疗组之间在客观进展、总生存期或疾病特异性生存期方面无显著差异。然而，亚组分析表明，与其他患者相比，疾病轻微或预后良好的患者可能从联合雄激素阻断中获益更多。与醋酸戈舍瑞林单药治疗相比，联合雄激素阻断显著降低了疾病发作的发生率。 结论 短期或长期联合雄激素阻断与单独使用醋酸戈舍瑞林相比均无生存优势。
OBJECTIVE The aims of this randomized, controlled study were to investigate the efficacy and safety of long-term monotherapy with the luteinizing hormone-releasing hormone agonist goserelin acetate compared with both short- and long-term combined androgen blockade. METHODS Patients with advanced prostate cancer (n = 371) were randomized to treatment with goserelin acetate alone or a combination of goserelin acetate plus either long-term or short-term antiandrogen (chlormadinone acetate) or short-term estrogen (diethylstilbestrol diphosphate). RESULTS There were no significant differences between the treatment groups with respect to objective progression, overall survival or disease-specific survival. Nevertheless, subgroup analysis suggested that patients with minimal disease or a good prognosis might benefit more from combined androgen blockade than other patients. Combined androgen blockade significantly reduced the incidence of disease flare compared with goserelin acetate treatment alone. CONCLUSIONS Neither short- nor long-term combined androgen blockade had a survival advantage over goserelin acetate alone.